Clinical Study of Efficacy and Safety of Rafamin in the Treatment of ARVI in Children 12-18 Years Old
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective
of this study is to evaluate efficacy and safety of Rafamin in the treatment of acute
respiratory viral infection (ARVI) in children aged 12-18 years old.